Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
NCT03090139
·
clinicaltrials.gov ↗
COMPLETED
Status
1731
Enrollment
INDUSTRY
Sponsor class
Conditions
Colitis, Ulcerative
Crohn Disease
Inflammatory Bowel Diseases
Interventions
DRUG:
Anti-TNF Therapy
Sponsor
Takeda